Articles tagged with Cell Therapies
Researchers from the Sylvester Comprehensive Cancer Center presented their findings on the association between smoking intensity, genetic mutations, and disease progression in myelodysplastic syndromes. Dr. Stephen D. Nimer received the 2024 ASH Mentor Award for his impact on hematology trainees.
Researchers developed a single-cell RNA-sequencing atlas of the Multiple Myeloma immune microenvironment across disease stages. The atlas reveals potential resistance mechanisms and identifies conventional dendritic cells as a targetable population in MM.
The review explores the impact of extracellular matrix (ECM) geometry on immune cell behavior and treatment efficacy. Specific ECM configurations, known as Tumor-Associated Collagen Signatures (TACS), create physical barriers that limit immune cell access to tumors.
Researchers at POSTECH have identified GLUT3 as essential for the suppressive function of regulatory T cells in tumor microenvironments, which can be targeted for cancer immunotherapy. The team's findings highlight the critical role of GLUT3 in regulating protein modifications that sustain immune suppression within tumors.
Researchers have discovered a new strategy to overcome docetaxel resistance in advanced prostate cancer patients, which may improve the efficacy of chemotherapy and prolong overall survival. The approach involves inhibiting cholesterol and lipid biosynthesis, reinducing sensitivity to the drug docetaxel.
The Wyss Institute's iNodes team has been awarded an ARPA-H Sprint for Women's Health to develop implantable immune organs for treating ovarian cancer. The iNodes concept is based on the formation of lymphoid organs in tumors, which can be reprogrammed to attack cancer cells and retain a long-term immune memory.
The VANCE trial demonstrates that Singapore has the expertise and capabilities to run large-scale global cell therapy trials. The study shows promising results for patients with recurrent or metastatic NPC treated with EBV-CTL therapy, with median survival rates of up to 29.9 months.
Researchers at MD Anderson Cancer Center present promising new treatments, including a gastric cancer therapy using T cell antigen coupler technology. Additionally, COVID-19 mRNA vaccines are shown to improve responses to immune checkpoint inhibitors in patients with non-small cell lung and melanoma cancers.
A collaborative study led by Dr. Julie St-Pierre at the University of Ottawa found that promoting mitochondrial elongation in cancer cells hobbles their ability to metastasize. The research team identified a common signature that could help determine which pathways lead to decreased metastasis.
Boston Medical Center and Boston University researchers have made a breakthrough in developing cell-based therapy for hypothyroidism. They derived transplantable thyroid follicular epithelial cells from human induced pluripotent stem cells, which can be transplanted into thyroid-deficient animal models.
Rice bioengineers create a mathematical model that challenges long-held assumptions about IL-12's behavior in the body, suggesting repeated doses cause immune cells to hoard IL-12 before it reaches the bloodstream. The findings have significant implications for IL-12 therapy design and may lead to more effective dosing regimens.
A new study introduces a multi-omics-based molecular classification of gastrointestinal stromal tumors, categorizing them into four distinct subtypes. The findings identify key genetic signatures and tumor suppressor genes that influence treatment response, providing a roadmap for personalized therapy strategies.
Scientists at Johns Hopkins Medicine identified 16 genes that breast cancer cells use to survive in the bloodstream, including MUC1, which is already in clinical trials. The research showed that hypoxic cells are able to migrate to higher oxygen levels and form metastasis in the body, leading to a worse prognosis.
A new study suggests that boosting T-regulatory cells may improve the chance of healthy pregnancy and reduce miscarriage risk. Researchers found that treatment with interleukin-2 and antibodies targeting these cells improved pregnancy outcomes in mice, reducing miscarriage rates from 30% to 11%.
Researchers at MIT have designed tiny particles that can be implanted at a tumor site, delivering heat and chemotherapy to treat cancer. The treatment approach has been shown to completely eliminate tumors in most mice and prolong their survival.
A new guide provides a roadmap for developing cell-penetrating peptide clusters to deliver lifesaving treatments across biological barriers. The clusters could improve patient outcomes dramatically by allowing minimum doses of treatments, reducing toxicity.
Researchers at Terasaki Institute have developed simvastatin-loaded nanoparticles to target adipose tissue inflammation, promoting fat tissue browning and weight loss. The treatment effectively inhibits obesity-related inflammation, controlled white fat production, and demonstrated strong anti-inflammatory effects.
Researchers developed grain-sized soft robots that can transport up to four different drugs, release them in reprogrammable orders and doses, and navigate complex environments inside the human body. The robots' precision functions have the potential to significantly improve therapeutic outcomes while minimizing side effects.
Researchers developed an in vitro model of murine peritoneal macrophage aging to study molecular mechanisms and develop innovative strategies. Chronic treatment with CB3 completely prevented the increase of p21CIP1 and maintained proliferative activity in day 14 macrophages.
Researchers humanize the lupus-derived autoantibody 3E10, preserving its therapeutic efficacy, to create novel cell-penetrating antibodies targeting tumors and RAD51. Humanized variants exhibit faster cell uptake and superior in vivo tumor targeting.
Researchers at Penn State College of Medicine have re-engineered natural killer immune cells with blue light-activated protein function, allowing them to infiltrate and kill solid tumor spheroids. The technology has shown promising results in killing breast cancer and melanoma cells within seven days.
Researchers at Weill Cornell Medicine have discovered a biomarker that can predict which patients with liver cancer are likely to benefit from immunotherapy. The study found that high levels of the immune-suppressing protein NBR1 may identify patients who will not respond to treatment, while lowering NBR1 levels may help shrink tumors.
Researchers discovered a previously unknown class of compounds in the fungus Bipolaris victoriae S27 that effectively kill colorectal cancer cells. The most effective compound, bipoterpride No. 2, targets the DCTPP1 enzyme and shows promise as a potential new treatment option.
Researchers have engineered probiotic bacteria to educate the immune system to destroy cancer cells, opening the door for a new class of cancer vaccines. The bacterial vaccine proved more efficacious than peptide-based therapeutic cancer vaccines in studies using mouse models of advanced colorectal and melanoma cancers.
Research highlights molecular chaperones' role in maintaining tumor suppressor stability and functional integrity. This understanding is crucial for developing targeted therapies for multiple cancers.
Researchers found Itaconate stimulates immune cells to produce anti-viral proteins called interferons by blocking an enzyme called SDH, offering a potential therapy for autoimmune and infectious diseases.
A recent clinical trial found that the Nivolumab and Anlotinib combination therapy significantly reduced tumor size in nearly one-third of patients, while most experienced stability in their condition. The treatment also showed improved survival outcomes compared to historical data, with a manageable safety profile.
Researchers have identified a protein called PERM1 that regulates both energy and heart muscle contraction, offering a new therapeutic approach to systolic heart failure. By addressing the underlying problem of weakened heart muscle, PERM1 may help restore cardiac function and improve patient outcomes.
A groundbreaking study has demonstrated the clinical success of a new nanoparticle-based, laser-guided therapy for prostate cancer treatment. The therapy successfully eliminated cancerous cells in 73% of patients after 12 months while preserving key functions and side effects.
A novel nanoparticle therapy targets fat absorption in the small intestine, showing significant potential to prevent diet-induced obesity. The treatment involves inhibiting an enzyme called Sterol O-acyltransferase 2 (SOAT2), which plays a critical role in fat absorption.
A new treatment strategy combining ReCET and semaglutide has been shown to eliminate insulin therapy in 86% of type 2 diabetes patients, improving sensitivity to endogenous insulin. The novel procedure, which employs electroporation, is compliance-free and disease-modifying, addressing ongoing patient adherence issues.
A new study suggests that a hydrogen sulfide-generating molecule targeting mitochondria can significantly slow weight gain and reduce liver fat accumulation in mice. The treatment, AP39, inhibits key metabolic pathways associated with obesity and inflammation, offering a promising new option for treating metabolic diseases.
Researchers have developed a novel gene therapy approach that targets and breaks down faulty ribonucleic acids in the KCNA2 gene, which is associated with recurring seizures. The therapy has shown promise in reducing excessive neuron activity linked to epilepsy.
A study by Ohio State University researchers found that combining pimozide with CB-839 can effectively suppress glioblastoma growth by blocking lipid production and starvation of tumor cells. This innovative combination may also hold promise for treating other cancers relying on glutamine and lipids.
A new CAR-T cell therapy targeting CD7 on leukaemia cells has shown promising results in treating T-ALL patients who have exhausted all standard treatment options. The therapy achieved complete remission in 16 out of 17 patients, with some remaining in remission for over five years.
A study published in Blood reported high response rates of 89% and complete responses of 70% among patients with relapsed or refractory multiple myeloma who received cilta-cel infusions. The results were comparable to those seen in clinical trials, suggesting the therapy's effectiveness in real-world settings.
Researchers review UBA1 loss of function in VEXAS Syndrome, a hematoinflammatory disorder characterized by severe inflammation, cytopenias, and oncogenicity. They explore therapeutic options, including clone-targeting drugs, to combat this challenging disease.
Researchers developed a new combined therapy for multiple sclerosis, combining tolerogenic dendritic cells with Dimethyl Fumarate to restore immune balance. The treatment showed promise in preclinical studies, reducing symptoms in mice and potentially offering hope for patients worldwide.
Two UCF cancer researchers, Alicja Copik and Debbie Altomare, have received $100,000 grants from the Florida Breast Cancer Foundation to develop new treatments for breast cancer. They focus on enhancing natural killer cells to fight cancer and harnessing the body's immune system to create new therapies.
A retrospective analysis of over 2,600 patients found that Black children were more likely to suffer severe graft-versus-host disease but overall survival rates improved across all racial groups. The study suggests that cord blood transplants are a vital lifeline for many patients and improve care for those without a matched donor.
A study published in Blood Advances found that CAR-T therapy can be administered safely and effectively on an outpatient basis in community hospitals, mitigating barriers to access. The treatment showed high efficacy rates, with 80% of patients experiencing an objective response and 54% achieving a complete response.
Huaier has been traditionally used to treat various health conditions, including cancer. Its unique chemical composition and molecular mechanisms of action have shown potent antitumor effects in both in-vitro and in-vivo studies. Further research is needed to fully understand its efficacy and safety in cancer therapy.
Researchers have identified key molecular targets that could significantly enhance the healing of both acute and chronic wounds. The study found that combinatorial therapy involving FGF7 and an MMP10-neutralising antibody can improve wound healing in both acute and chronic wounds.
The CRISPR-Cas13 system enables temporary gene expression manipulation without permanent genomic changes, holding promise for treating diseases caused by RNA defects. It has been applied to correct mutations linked to Duchenne muscular dystrophy and can be used to alter splicing events, making it a powerful tool in personalized medicine.
Researchers at St. Jude Children's Research Hospital found that patients with ETV6::RUNX1 and high-hyperdiploid B-ALL can achieve positive outcomes with low-intensity chemotherapy, tailoring treatment based on genetic subtypes and early treatment response. This approach reduces side effects and improves event-free survival rates.
Researchers discovered that DNA methylation patterns, like cellular memory markers, prevent reprogrammed cells from fully adopting new identities. This limitation limits the effectiveness of long-term treatments and therapies.
Researchers at Rice University and Baylor College of Medicine are developing a new cell therapy platform to suppress inflammation and lung damage in ARDS patients. The platform uses engineered retinal pigment epithelial cells to locally produce anti-inflammatory agents, promising improved patient outcomes.
Scientists at Brigham and Women's Hospital have created a strategy to boost mitochondrial activity in T cells, improving their ability to penetrate and kill tumor cells. The new approach helps to overcome a major barrier in immunotherapy by increasing the energy capacity of T cells.
CAR-T cell therapy, a regenerative immunotherapy, has shown promise in treating blood cancers but struggles with T-cell exhaustion. Researchers have discovered that overproduction of the IL-4 protein causes this exhaustion and used CRISPR gene-editing technology to remove it, improving CAR-T cell therapy outcomes.
Researchers highlight key phagocytosis checkpoints and 'do not eat me' signals as potential therapeutic targets for novel immunotherapies. The editorial summarizes challenges in targeting CD47 and potential solutions to overcome these obstacles.
Researchers have discovered that administering regulatory T cells (Tregs) can enhance tissue healing, promoting bone volume, muscle growth, and skin wound closure. The key role of interleukin-10 (IL-10) in supporting tissue repair has also been identified.
A systematic review and meta-analysis found that CAR T-cell therapy patients developed second primary malignancies at a similar rate as those receiving standard-of-care therapies. Studies with patients who received more prior lines of treatment showed higher SPM rates, while longer follow-up times may indicate survivorship bias.
Scientists from Spirovant Sciences describe a novel adeno-associated virus (AAV) gene therapy called SP-101 that has been optimized for efficient human airway cell transduction. After single dose inhaled delivery, the vector showed consistent expression of a functional and regulated shortened human CFTR minigene.
Researchers at Johns Hopkins Medicine found that age-related changes in male fibroblasts contribute to more aggressive and treatment-resistant melanomas. The study discovered that male fibroblasts accumulate reactive oxygen species and produce higher levels of BMP2, leading to increased DNA damage and resistance to targeted therapies.
Researchers at Nagoya University have developed a method to chemically alter siRNAs, reducing off-target effects and improving the safety of siRNA drugs for genetic therapy. By modifying the seed region of siRNAs with formamide, they achieved suppression of off-target effects with higher efficiency than existing chemical modifications.
Researchers developed a gene therapy that restored useful vision to most patients with Leber congenital amaurosis type I, a rare inherited blindness. The treatment showed a 10,000-fold improvement in light sensitivity and improved navigation abilities in patients who received the highest dose.
Researchers discovered faulty immune processes responsible for lingering lung issues after COVID-19, which can be disrupted by existing drugs. The study also identified molecules responsible for the issue and potential therapeutic options for patients with ongoing lung damage.
Researchers investigate how hypernatremia affects microglial responses and evaluate potential therapies. Microglia's response to hyperosmotic stress is found to be associated with NFAT5 expression and NO production.
A clinical trial led by UC San Francisco aims to develop new therapies for progressive supranuclear palsy, with a focus on reducing time to find effective treatments and increasing diverse participant enrollment. The five-year grant could lead to the first effective drugs for this incurable neurodegenerative disorder.
Experts propose a series of scientific principles and experimental approaches to assess potential carcinogenicity of gene therapies. Data transparency is crucial, with publicly accessible data from viral integrations site studies and clinical settings.